BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.2//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20210101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220315
DTEND;VALUE=DATE:20220318
DTSTAMP:20260516T010212
CREATED:20211122T103557Z
LAST-MODIFIED:20211227T114657Z
UID:32201-1647302400-1647561599@www.pharmajournalist.com
SUMMARY:2nd TPD Europe Summit
DESCRIPTION:2021 marked a successful year for the protein degradation field with several candidates entering the clinic. As the European centric targeted protein degradation landscape matures and the number of pre-clinical candidates expected to enter clinical development in the next year grows ever more\, the 2nd TPD Europe Summit returns\, in person\, to highlight key challenges and opportunities ahead! \nBuilt with biopharma in mind\, join us as we take a deep dive into how European leaders of protein degradation are approaching key translational challenges including optimisation of selectivity\, bioavailability and PKPD to ensure the safety\, efficacy and potency of their clinical pipelines in 2022 and beyond! \nBe at the heart of the discussion by joining 180+ Senior Scientists\, Principal Investigators & Heads of Discovery\, Pre-Clinical & Translational Development from Europe and around the globe for two dedicated streams of exciting content over three days to capitalise on this emerging therapeutic class. \nKey Highlights Not to Miss: \n\nHear from Kevin Moreau\, Assoicate Director PROTAC Safety Science\, AstraZeneca as he discusses key PROTAC safety considerations for both oncology and non-oncology indications including how to optimise the safety profile\, and what is acceptable for non-oncology targets\n\n\nDelve into COFFEE (covalent functionalisation followed by E3 electroporation)\, which tests neo-substrate degradation by chemically modified E3 ligase components. Brought to you by Benika Pinch\, Principal Scientist\, Novartis\, she discusses how to assess the cellular activity of E3 ligase components\n\n\nUncover how protein manipulation using peptides can be used to degrade proteins using either the UPS or lysosomal pathways. This exciting approach relocates protein within the cell and modulates their interactions. Hear Max Cynader\, CEO & Co-Founder Primary Peptides discuss in detail!\n\n\nAmine Sadok\, Head of Biology at Monte Rosa Therapeutics will be discussing how they have identified a potent and selective NEK7 molecular glue degrader as a novel CRBN neo-substrate\n\nDigital passes available \nTo know more visit: https://ter.li/j3ytqu
URL:https://www.pharmajournalist.com/event/2nd-tpd-europe-summit/
LOCATION:London\, UK
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
END:VCALENDAR